OMIC — Singular Genomics Systems Cashflow Statement
0.000.00%
Last trade - 00:00- $50.26m
- -$53.51m
- $2.91m
Annual cashflow statement for Singular Genomics Systems, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.3 | -27.9 | -98.8 | -90.9 | -94.8 |
| Depreciation | |||||
| Non-Cash Items | 0.16 | 1.57 | 48.8 | 18.2 | 19.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.415 | 0.858 | -2.91 | -16.8 | -2.25 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -11.4 | -24.9 | -51.7 | -87.1 | -73.6 |
| Capital Expenditures | -0.8 | -1.38 | -4.86 | -6.02 | -0.97 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -30.7 | 25.4 | -126 | -33.5 | 14.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -31.5 | 24 | -131 | -39.6 | 13.8 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 47.3 | 7.51 | 372 | 0.901 | 0.696 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.41 | 6.65 | 190 | -126 | -59.1 |